American Society of Gene + Cell Therapy
@asgct.bsky.social
Advancing knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
⏱️ It's time to finalize your #ASGCT2026 abstract. Hit that submit button today! https://annualmeeting.asgct.org/abstracts/submission-information
January 20, 2026 at 6:10 PM
⏱️ It's time to finalize your #ASGCT2026 abstract. Hit that submit button today! https://annualmeeting.asgct.org/abstracts/submission-information
ASGCT launches CGTxchange to rescue shelved therapies, urges Senate action on PRV reauthorization, and provides critical updates on federal funding and FDA manufacturing programs.
Read more in the latest edition of The Advocate: https://bit.ly/45ItIkK
Read more in the latest edition of The Advocate: https://bit.ly/45ItIkK
The Advocate: January 2026
ASGCT launches CGTxchange to rescue shelved therapies, urges Senate action on PRV reauthorization, and provides critical updates on federal funding and…
www.asgct.org
January 15, 2026 at 4:56 PM
ASGCT launches CGTxchange to rescue shelved therapies, urges Senate action on PRV reauthorization, and provides critical updates on federal funding and FDA manufacturing programs.
Read more in the latest edition of The Advocate: https://bit.ly/45ItIkK
Read more in the latest edition of The Advocate: https://bit.ly/45ItIkK
Don't miss out on the opportunity to present your groundbreaking work at this essential gathering of cell and gene therapy professionals. Submit your abstract today! https://annualmeeting.asgct.org/abstracts/submission-information
January 10, 2026 at 6:48 PM
Don't miss out on the opportunity to present your groundbreaking work at this essential gathering of cell and gene therapy professionals. Submit your abstract today! https://annualmeeting.asgct.org/abstracts/submission-information
Join ASGCT President Dr. Terry Flotte at the Empowering Patients Summit! He kicks off two virtual half-days of expert-led sessions on March 11 at 10 a.m. ET. Reserve your spot (free!): asgct.org/empowering
#EmpoweringASGCT
#EmpoweringASGCT
January 8, 2026 at 9:12 PM
Join ASGCT President Dr. Terry Flotte at the Empowering Patients Summit! He kicks off two virtual half-days of expert-led sessions on March 11 at 10 a.m. ET. Reserve your spot (free!): asgct.org/empowering
#EmpoweringASGCT
#EmpoweringASGCT
We’re proud to announce a new partnership with Orphan Therapeutics Accelerator to launch CGTxchange – a first-of-its-kind, jointly owned marketplace for deprioritized CGTs, accelerating development for ultra-rare diseases. #ASGCT #OTXL
Learn more: https://bit.ly/3LuypaS
Learn more: https://bit.ly/3LuypaS
American Society of Gene & Cell Therapy and Orphan Therapeutics…
First-of-its-kind venture to facilitate and catalyze development of deprioritized cell and gene therapies, supported by AI-enabled platform
www.asgct.org
January 7, 2026 at 7:17 PM
We’re proud to announce a new partnership with Orphan Therapeutics Accelerator to launch CGTxchange – a first-of-its-kind, jointly owned marketplace for deprioritized CGTs, accelerating development for ultra-rare diseases. #ASGCT #OTXL
Learn more: https://bit.ly/3LuypaS
Learn more: https://bit.ly/3LuypaS
Curious about cell and gene therapy? Dr. Phil Tai will guide you through Module 1 in our new Foundations of CGT online course – self-paced, convenient, and free! Check it out: asgct.org/learning
Funded by an independent educational grant from Pfizer, Inc.
Funded by an independent educational grant from Pfizer, Inc.
January 7, 2026 at 6:21 PM
Curious about cell and gene therapy? Dr. Phil Tai will guide you through Module 1 in our new Foundations of CGT online course – self-paced, convenient, and free! Check it out: asgct.org/learning
Funded by an independent educational grant from Pfizer, Inc.
Funded by an independent educational grant from Pfizer, Inc.
Dr. Niki Paulk, CEO and Founder of Siren Biotechnology joins the podcast for a timely conversation on turning scientific promise into commercial success. 🎧 Listen now: https://bit.ly/49oQeAm
Entrepreneurship, Fundraising, and the Future of Cell & Gene… | ASGCT
Dr. Paulk offers perceptive insights into the complex world of biotech entrepreneurship, covering essential fundraising strategies from Seed and Series…
www.asgct.org
January 6, 2026 at 6:32 PM
Dr. Niki Paulk, CEO and Founder of Siren Biotechnology joins the podcast for a timely conversation on turning scientific promise into commercial success. 🎧 Listen now: https://bit.ly/49oQeAm
Looking to expand your professional network and leadership experience in the CGT field? Apply to serve on an ASGCT committee! Our committees drive the programs and initiatives that advance the field.
Submit your application by January 15: https://www.asgct.org/membership/asgct-committees
Submit your application by January 15: https://www.asgct.org/membership/asgct-committees
ASGCT Committees
As a rapidly growing community, ASGCT offers a unique opportunity for members at any career stage to contribute meaningfully to the cell and gene therapy…
www.asgct.org
December 29, 2025 at 4:41 PM
Looking to expand your professional network and leadership experience in the CGT field? Apply to serve on an ASGCT committee! Our committees drive the programs and initiatives that advance the field.
Submit your application by January 15: https://www.asgct.org/membership/asgct-committees
Submit your application by January 15: https://www.asgct.org/membership/asgct-committees
“We’re in such an exciting moment, and how to marry the potential of all of this with getting the details right for each application is the tension of our moment.”
Hear Dr. Sonia Vallabh's powerful personal journey to develop a treatment for prion disease: https://bit.ly/3X4YPCp
Hear Dr. Sonia Vallabh's powerful personal journey to develop a treatment for prion disease: https://bit.ly/3X4YPCp
December 28, 2025 at 1:24 PM
“We’re in such an exciting moment, and how to marry the potential of all of this with getting the details right for each application is the tension of our moment.”
Hear Dr. Sonia Vallabh's powerful personal journey to develop a treatment for prion disease: https://bit.ly/3X4YPCp
Hear Dr. Sonia Vallabh's powerful personal journey to develop a treatment for prion disease: https://bit.ly/3X4YPCp
Happy holidays from all of us at ASGCT! We wish our entire community a joyful and restful season. The ASGCT office will be closed Dec. 24 – Jan. 5. We look forward to a bright and productive 2026.
December 24, 2025 at 12:21 AM
Happy holidays from all of us at ASGCT! We wish our entire community a joyful and restful season. The ASGCT office will be closed Dec. 24 – Jan. 5. We look forward to a bright and productive 2026.
The @fda.gov has approved Waskyra, the first gene therapy for #WiskottAldrichSyndrome and the first-ever gene therapy to be brought through regulatory approval by a nonprofit organization. Read more from ASGCT President Terry Flotte, MD: https://bit.ly/3NcZzn7
FDA Approves Waskyra, First Gene Therapy for Wiskott-Aldrich Syndrome
This approval represents a significant milestone as the first gene therapy developed and brought through regulatory approval by a nonprofit organization.
www.asgct.org
December 22, 2025 at 9:04 PM
The @fda.gov has approved Waskyra, the first gene therapy for #WiskottAldrichSyndrome and the first-ever gene therapy to be brought through regulatory approval by a nonprofit organization. Read more from ASGCT President Terry Flotte, MD: https://bit.ly/3NcZzn7
The entire CGT community is invited to join us in Boston, May 11-15, 2026, for the ASGCT 2026 Annual Meeting! ✔️ Check registration off your list today + save with our early bird discount.
December 22, 2025 at 5:07 PM
The entire CGT community is invited to join us in Boston, May 11-15, 2026, for the ASGCT 2026 Annual Meeting! ✔️ Check registration off your list today + save with our early bird discount.
🎙️ The Issue is back! Listen to the latest episode as Dr. Jim Burns, CEO of Ensoma, discusses the company's novel technological approach to treating both rare diseases and solid tumor oncology. https://bit.ly/4j1uRtg
Unlocking New Therapeutic Potential: Ensoma’s Platform for… | ASGCT
Host Emily Walsh Martin welcomes Dr. Jim Burns, CEO of Ensoma, to discuss the company's novel technological approach to treating both rare diseases and…
www.asgct.org
December 16, 2025 at 5:05 PM
🎙️ The Issue is back! Listen to the latest episode as Dr. Jim Burns, CEO of Ensoma, discusses the company's novel technological approach to treating both rare diseases and solid tumor oncology. https://bit.ly/4j1uRtg
The latest edition of The Patient Press is out now! Catch up on CGT news for patients, caregivers, advocates, and the rare disease community: https://patienteducation.asgct.org/the-patient-press-newsletter/the-patient-press-december-2025
The Patient Press: December 2025
Check out key policy updates, including the Rare Pediatric Disease PRV reauthorization, plus new resources on AAV immune responses and Epidermolysis…
patienteducation.asgct.org
December 16, 2025 at 3:15 PM
The latest edition of The Patient Press is out now! Catch up on CGT news for patients, caregivers, advocates, and the rare disease community: https://patienteducation.asgct.org/the-patient-press-newsletter/the-patient-press-december-2025
Start the new year strong with our new Foundations of CGT online course – self-paced, interactive, and free! Check out the ASGCT Learning Center: https://www.asgct.org/education-career-resources/asgct-learning-center
December 15, 2025 at 5:56 PM
Start the new year strong with our new Foundations of CGT online course – self-paced, interactive, and free! Check out the ASGCT Learning Center: https://www.asgct.org/education-career-resources/asgct-learning-center
🌎 Join us on Tuesday, Dec. 16, for the next installment of our Around the World webinar series! Guilherme Baldo, Ph.D., of Universidade Federal do Rio Grande do Sul, moderates a deep dive into South American CGT frontiers. Attend at no cost: https://bit.ly/489b0mT
December 12, 2025 at 7:26 PM
🌎 Join us on Tuesday, Dec. 16, for the next installment of our Around the World webinar series! Guilherme Baldo, Ph.D., of Universidade Federal do Rio Grande do Sul, moderates a deep dive into South American CGT frontiers. Attend at no cost: https://bit.ly/489b0mT
FDA approves an expanded indication for Breyanzi, the first CAR T-cell therapy for relapsed/refractory marginal zone lymphoma. The CD19-directed therapy offers a one-time treatment for patients. Read more: https://bit.ly/48JGyzS
Bristol Myers Squibb’s Application for Breyanzi Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Margi...
Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results from MZL cohort of TRANSCEND FL presented at ICML in ...
bit.ly
December 11, 2025 at 9:33 PM
FDA approves an expanded indication for Breyanzi, the first CAR T-cell therapy for relapsed/refractory marginal zone lymphoma. The CD19-directed therapy offers a one-time treatment for patients. Read more: https://bit.ly/48JGyzS
"Multiple sessions established that precise genomic modification in various tissues is transitioning from an experimental concept to a clinical reality." – Kiran Musunuru, MD, Ph.D.
Read more + access recordings from the live event: https://bit.ly/3YmtziR
Read more + access recordings from the live event: https://bit.ly/3YmtziR
Celebrating Breakthrough Moments: Highlights from ASGCT Breakthroughs…
ASGCT’s 2025 Breakthroughs in In Vivo Gene Editing Conference delivered precisely what its name promised: breakthrough moments that are reshaping our…
www.asgct.org
December 11, 2025 at 5:14 PM
"Multiple sessions established that precise genomic modification in various tissues is transitioning from an experimental concept to a clinical reality." – Kiran Musunuru, MD, Ph.D.
Read more + access recordings from the live event: https://bit.ly/3YmtziR
Read more + access recordings from the live event: https://bit.ly/3YmtziR
The @fda.gov has approved Waskyra, the first gene therapy for Wiskott-Aldrich syndrome and a major milestone for nonprofit-led development. Clinical trials showed sharp drops in severe infections and bleeding. ASGCT supports solutions to help these therapies reach patients. https://bit.ly/48RoGDj
In a first, FDA approves a gene therapy from a nonprofit
The FDA on Tuesday approved Waskyra for a rare immune disease called Wiskott-Aldrich syndrome, for which patients have little options besides a bone marrow transplant.
endpoints.news
December 10, 2025 at 10:57 PM
The @fda.gov has approved Waskyra, the first gene therapy for Wiskott-Aldrich syndrome and a major milestone for nonprofit-led development. Clinical trials showed sharp drops in severe infections and bleeding. ASGCT supports solutions to help these therapies reach patients. https://bit.ly/48RoGDj
Your research deserves the spotlight! 🌟 The ASGCT Annual Meeting offers a crucial opportunity to showcase your research to a prestigious global audience, boosting the visibility of your work and helping you forge career-shaping connections. Learn more: https://bit.ly/3KmVlbP
December 10, 2025 at 6:43 PM
Your research deserves the spotlight! 🌟 The ASGCT Annual Meeting offers a crucial opportunity to showcase your research to a prestigious global audience, boosting the visibility of your work and helping you forge career-shaping connections. Learn more: https://bit.ly/3KmVlbP
We recently hosted a Congressional briefing on #GeneTherapy approaches for #HIV with experts from @usc.edu, @ohsunews.bsky.social, and patient advocates. Read our recap to learn how decades of NIH-funded research is bringing us closer to a cure: https://bit.ly/4oJbLt4 #ASGCTAdvocacy
ASGCT Briefs Congress on Gene Therapies to Treat HIV
Today, more than 1.2 million Americans live with HIV. Gene and cell therapy approaches hold the potential to deliver one-time therapies that could free…
www.asgct.org
December 9, 2025 at 5:23 PM
We recently hosted a Congressional briefing on #GeneTherapy approaches for #HIV with experts from @usc.edu, @ohsunews.bsky.social, and patient advocates. Read our recap to learn how decades of NIH-funded research is bringing us closer to a cure: https://bit.ly/4oJbLt4 #ASGCTAdvocacy
Huge thanks to @coons.senate.gov for helping spotlight how gene therapy is shifting HIV treatment from lifelong management toward durable, potentially curative outcomes. We appreciate your commitment to advancing biomedical research. #ASGCTadvocacy
December 5, 2025 at 7:21 PM
Huge thanks to @coons.senate.gov for helping spotlight how gene therapy is shifting HIV treatment from lifelong management toward durable, potentially curative outcomes. We appreciate your commitment to advancing biomedical research. #ASGCTadvocacy
📢 Registration for the ASGCT 2026 Annual Meeting is officially open! Secure your spot to join thousands of cell and gene therapy experts in Boston, May 11-15, 2026. Register today: https://annualmeeting.asgct.org/register-attend/rates-registration
December 3, 2025 at 7:18 PM
📢 Registration for the ASGCT 2026 Annual Meeting is officially open! Secure your spot to join thousands of cell and gene therapy experts in Boston, May 11-15, 2026. Register today: https://annualmeeting.asgct.org/register-attend/rates-registration
Join us this Thursday for a FREE webinar exploring the evolution of aptamers, from their initial discovery to their current role as precise, versatile tools surpassing antibodies in diagnostic and therapeutic applications. Register: https://bit.ly/3XLi7Np
Molecular Therapy Presents: Innovations in Aptamer Technology
Thursday, December 4 at 1 p.m. CT
www.asgct.org
December 1, 2025 at 3:05 PM
Join us this Thursday for a FREE webinar exploring the evolution of aptamers, from their initial discovery to their current role as precise, versatile tools surpassing antibodies in diagnostic and therapeutic applications. Register: https://bit.ly/3XLi7Np
FDA approves Itvisma, expanding access to gene therapy for spinal muscular atrophy. The one-time intrathecal treatment is approved for patients two years and older – the first gene replacement therapy available for this broader SMA population. Read more: https://bit.ly/3Kn9mpM
FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy
FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy
www.fda.gov
November 28, 2025 at 7:30 PM
FDA approves Itvisma, expanding access to gene therapy for spinal muscular atrophy. The one-time intrathecal treatment is approved for patients two years and older – the first gene replacement therapy available for this broader SMA population. Read more: https://bit.ly/3Kn9mpM